We can't find the internet
Attempting to reconnect
Retour aux projets
28452.1 IP-LS
28452.1 IP-LS
Résumé
Feasibility study: Development of a lead compound for specific mTORC1 inhibition
Textes supplémentaires
Abstract
The mammalian target of rapamycin complex 1 (mTORC1) is deregulated in multiple diseases. We aim to generate a lead compound that specifically inhibits mTORC1 by targeting substrate recruitment. We expect such a compound to be superior to current drugs for treating tuberous sclerosis complex.
Participants
Timm Maier
Kontaktperson
timm.maier@unibas.ch
Universität Basel Biozentrum Timm Maier Spitalstrasse 41 4056 Basel BS CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2018-10-31
- Date de fin
- 2020-04-30
- Coûts totaux approuvés
- CHF 349982.08
- Section
- 60 Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T410 Pharmaceuticals and related technologies 100.0%